Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Quality improvement in neurology: amyotrophic lateral sclerosis quality measures. Report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology.
Miller RG, Brooks BR, Swain-Eng RJ, Basner RC, Carter GT, Casey P, Cohen AB, Dubinsky R, Forshew D, Jackson CE, Kasarskis E, Procaccini NJ, Sanjak M, Tolin FP. Miller RG, et al. Among authors: sanjak m. Amyotroph Lateral Scler Frontotemporal Degener. 2014 Jun;15(3-4):165-8. doi: 10.3109/21678421.2013.875706. Epub 2014 Apr 7. Amyotroph Lateral Scler Frontotemporal Degener. 2014. PMID: 24707820 No abstract available.
Quality improvement in neurology: amyotrophic lateral sclerosis quality measures: report of the quality measurement and reporting subcommittee of the American Academy of Neurology.
Miller RG, Brooks BR, Swain-Eng RJ, Basner RC, Carter GT, Casey P, Cohen AB, Dubinsky R, Forshew D, Jackson CE, Kasarskis E, Procaccini NJ, Sanjak M, Tolin FP. Miller RG, et al. Among authors: sanjak m. Neurology. 2013 Dec 10;81(24):2136-40. doi: 10.1212/01.wnl.0000437305.37850.f9. Epub 2013 Nov 22. Neurology. 2013. PMID: 24271651 Free PMC article. Review.
Quality control of vital capacity as a primary outcome measure during phase III therapeutic clinical trial in amyotrophic lateral sclerosis.
Sanjak M, Salachas F, Frija-Orvoen E, Theys P, Hutchinson D, Verheijde J, Pianta T, Stewart H, Brooks BR, Meininger V, Douillet P; Xaliproden [SR57746A] ALS International Study Group. Sanjak M, et al. Amyotroph Lateral Scler. 2010 Aug;11(4):383-8. doi: 10.3109/17482960903486083. Amyotroph Lateral Scler. 2010. PMID: 20192884
A randomized controlled trial of resistance and endurance exercise in amyotrophic lateral sclerosis.
Clawson LL, Cudkowicz M, Krivickas L, Brooks BR, Sanjak M, Allred P, Atassi N, Swartz A, Steinhorn G, Uchil A, Riley KM, Yu H, Schoenfeld DA, Maragakis NJ; neals consortium. Clawson LL, et al. Among authors: sanjak m. Amyotroph Lateral Scler Frontotemporal Degener. 2018 May;19(3-4):250-258. doi: 10.1080/21678421.2017.1404108. Epub 2017 Nov 30. Amyotroph Lateral Scler Frontotemporal Degener. 2018. PMID: 29191052 Clinical Trial.
Disease-modifying drug therapies.
Brooks BR, Sanjak M. Brooks BR, et al. Among authors: sanjak m. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Sep;5 Suppl 1:68-75. doi: 10.1080/17434470410019898. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004. PMID: 15512878 Clinical Trial. No abstract available.
40 results